 MedImmune Limited, a unit of AstraZeneca Plc NASDAQ: AZN, has notified Inovio Pharmaceuticals Inc NASDAQ: INO to terminate the DNA cancer vaccine development program agreement. Under the agreement, MedImmune acquired exclusive rights to INO-3112 immunotherapy, renamed MEDI0457, targeting cancers caused by human papillomavirus types 16 and 18. 